Carevive's platform links clinical data with patient-reported outcomes to enable remote symptom management, tailor cancer care programs, and reduce patients' trips to health centers. The company says its software and analytics help researchers design cancer care delivery models, support payers' reimbursement decisions, and assist life-science companies developing personalized therapies. Carevive PROmpt® is its remote patient management functionality and the company reports deployment in dozens of hospitals across the U.S.; it was selected by Pfizer as the first Patient-Reported Outcomes (PRO) challenge winner for that product. Founded in 2013, Carevive emphasizes building real-world evidence through its Oncology Pragmatic Trial Investigator Network (Carevive OPT-IN®) to evaluate patient experiences. The company appointed Bruno Lempernesse as CEO in December 2020. Following the Series C, Carevive plans investments in technology, data analytics, infrastructure, expanded remote patient management, and growth of its OPT-IN network to build stronger evidence for treatment and symptom pathways.

Total raised

$18M

Funding rounds

1

Latest round

Series C

Latest activity

Feb 2021